Canakinumab's Effect Against Subsequent Gout Flares and High‐Sensitivity C‐Reactive Protein Levels: A Causal Mediation Analysis
Authors:
- 7 December 2021
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 75 (4) , 817-824
Abstract
Objective: The objective of this study was to quantify the value of early suppression of high‐sensitivity C‐reactive protein (hsCRP) levels as a biomarker of the protective role of canakinumab against future gout flares.Methods: We conducted a post hoc causal mediation analysis of the Canakinumab Anti‐Inflammatory Thrombosis Outcome Study for gout flares. The 3‐month change in the log hsCRP level was the mediator of interest. We used linear regression for the hsCRP level mediator and Cox or Weibull regression for gout‐flare outcomes, combining them in causal mediation analysis. We examined the cohort overall, as well as stratified by prevalent gout at baseline.Results: We analyzed 9,221 patients without prevalent gout and 747 with prevalent gout. The Cox regression hazard ratio (HR) for a gout flare was 0.50 (95% confidence interval [95% CI] 0.37–0.68) comparing canakinumab with placebo, of which 6% was explained by the mediated effect through hsCRP level reduction in the first 3 months. In the prevalent‐gout subgroup, the HR was 0.58 (95% CI 0.36–0.95), of which 31% was explained by the mediated effect through hsCRP level reduction. The Weibull analysis gave a proportion‐mediated estimate of 47%. The indirect effect via hsCRP level reductions was unclear in the subgroup without prevalent gout.Conclusion: The first 3‐month reduction in hsCRP level was not a good biomarker for canakinumab's protective effect on future gout flares in the overall cohort. Among patients with prevalent gout, there may be a potential role for early hsCRP level reduction as a biomarker for interleukin‐1β inhibitors' future gout‐flare benefit.Keywords
Funding Information
- Brigham and Women's Hospital (Shore/Department of Medicine Fellowship Award)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23‐AR‐076453, P30‐AR‐072577)
- Rheumatology Research Foundation (K Bridge Award)
This publication has 23 references indexed in Scilit:
- From C-Reactive Protein to Interleukin-6 to Interleukin-1Circulation Research, 2016
- SAS Macro for Causal Mediation Analysis with Survival DataEpidemiology, 2015
- Imaging in gout: A review of the recent developmentsTherapeutic Advances in Musculoskeletal Disease, 2014
- Mediation analysis allowing for exposure–mediator interactions and causal interpretation: Theoretical assumptions and implementation with SAS and SPSS macros.Psychological Methods, 2013
- Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensionsAnnals of the Rheumatic Diseases, 2012
- Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging studyArthritis Research & Therapy, 2011
- Odds Ratios for Mediation Analysis for a Dichotomous OutcomeAmerican Journal of Epidemiology, 2010
- Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging studyArthritis & Rheumatism, 2010
- CanakinumabmAbs, 2010
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in WomenNew England Journal of Medicine, 2000